View ValuationLaekna 将来の成長Future 基準チェック /26Laeknaの収益は年間2.2%で減少すると予測されていますが、年間収益は年間55.7%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-130.9% 3%なると予測されています。主要情報-2.2%収益成長率2.95%EPS成長率Biotechs 収益成長25.3%収益成長率55.7%将来の株主資本利益率-130.93%アナリストカバレッジLow最終更新日29 Sep 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 15Laekna, Inc., Annual General Meeting, Jun 05, 2026Laekna, Inc., Annual General Meeting, Jun 05, 2026, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai, china, Hong Kongお知らせ • Mar 06Laekna, Inc. to Report Fiscal Year 2025 Results on Mar 18, 2026Laekna, Inc. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 18, 2026お知らせ • Jan 14Laekna, Inc. Announces That the U.S. Food and Drug Administration Has Accepted Its Investigational New Drug Application for LAE118The board of directors of Laekna, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for LAE118, a novel PI3K a pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. The Company will work closely with the regulatory authorities to complete the application. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options.お知らせ • Jan 02Laekna, Inc. Commences Study Recruitment in Phase I Single Ascending Dose Study of LAE103The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I single ascending dose study of LAE103, an internally discovered monoclonal antibody against ActRIIB, in Australia. As of the date of this announcement, first subject has been dosed. The SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. The Group targets to bring this precision therapy to cardiovascular and metabolic diseases with high unmet medical needs, such as obesity, sarcopenia and heart failure.お知らせ • Sep 18Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listingお知らせ • Sep 11Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listingお知らせ • Jul 29Laekna, Inc. to Report First Half, 2025 Results on Aug 13, 2025Laekna, Inc. announced that they will report first half, 2025 results on Aug 13, 2025お知らせ • Jun 30Laekna, Inc. Submits Investigational New Drug Application to the U.S. Food and Drug AdministrationThe board of directors of Laekna, Inc. announced that the Group has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to metabolic patients who are in need of novel treatment options. The Group plans to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans.お知らせ • Jun 24Laekna Presents Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123Laekna announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation and has taken place in Chicago, USA, from June 20 to 23 this year. Professor Xuening LI, Zhongshan Hospital affiliated to Fudan University,Principal Investigator of the Phase I Clinical Trial of LAE102 in China. At the ADA Scientific Sessions, Laekna showcased LAE102, LAE102, LAE 103, and LAE123 - an innovative portfolio targeting the ActRII pathway - highlighting team's extensive expertise and leadership in this field. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively.お知らせ • Jun 23Laekna, Inc. Announces Results of Phase I Sad Study of Lae102Laekna, Inc. announced that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). Presentations details are as follows: Poster No.1. Abstract Number: 2205-LB, Title: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy volunteers, Time: Sunday, June 22, 2025, 12:30 p.m.-13:30 p.m. CST, Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous (IV) and subcutaneous (SC) cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events (TEAEs) leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123. This positions LAE102 as a promising drug candidate for achieving quality weight control.お知らせ • May 13Laekna, Inc., Annual General Meeting, Jun 03, 2025Laekna, Inc., Annual General Meeting, Jun 03, 2025, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai Chinaお知らせ • Mar 26Laekna, Inc. Commences Study Recruitment in Phase I Multiple Ascending Dose Study of Lae102 for the Treatment of ObityThe board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I multiple ascending dose study of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.お知らせ • Mar 10Laekna, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025Laekna, Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025お知らせ • Jan 13Laekna, Inc. Announces Completion of A Successful Phase I Single Ascending Dose Study of Lae102 for the Treatment of ObesityThe board of directors of Laekna, Inc. announced that the Group has successfully completed the phase I single ascending dose study of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2+-2.2 kg/m2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study in China as well as the phase I clinical study in collaboration with Eli Lilly & Company in the U.S. The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible. The positive SAD Study results support continuing the investigation of LAE102 for thetreatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.業績と収益の成長予測OTCPK:LAEK.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202779-247-338-175412/31/202613-293-290-281412/31/2025N/A-278-239-26136/30/20255-240-211-209N/A3/31/20253-247-246-244N/A12/31/20241-254-280-278N/A9/30/20241-275-283-281N/A6/30/20241-296-285-283N/A3/31/20241-332-291-289N/A12/31/20230-369-297-296N/A9/30/20230-533-309-307N/A6/30/20230-697-320-318N/A3/31/20230-739-316-312N/A12/31/20220-782-311-306N/A12/31/20210-749-207-198N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: LAEK.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LAEK.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: LAEK.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LAEK.Fの収益 ( 55.7% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: LAEK.Fの収益 ( 55.7% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: LAEK.F 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/11/26 16:54終値2025/08/29 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Laekna, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Bo LiBofA Global Researchnull nullChina International Capital Corporation LimitedYaxin LiuChina International Capital Corporation Limited1 その他のアナリストを表示
お知らせ • May 15Laekna, Inc., Annual General Meeting, Jun 05, 2026Laekna, Inc., Annual General Meeting, Jun 05, 2026, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai, china, Hong Kong
お知らせ • Mar 06Laekna, Inc. to Report Fiscal Year 2025 Results on Mar 18, 2026Laekna, Inc. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 18, 2026
お知らせ • Jan 14Laekna, Inc. Announces That the U.S. Food and Drug Administration Has Accepted Its Investigational New Drug Application for LAE118The board of directors of Laekna, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for LAE118, a novel PI3K a pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. The Company will work closely with the regulatory authorities to complete the application. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options.
お知らせ • Jan 02Laekna, Inc. Commences Study Recruitment in Phase I Single Ascending Dose Study of LAE103The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I single ascending dose study of LAE103, an internally discovered monoclonal antibody against ActRIIB, in Australia. As of the date of this announcement, first subject has been dosed. The SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. The Group targets to bring this precision therapy to cardiovascular and metabolic diseases with high unmet medical needs, such as obesity, sarcopenia and heart failure.
お知らせ • Sep 18Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 11Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listing
お知らせ • Jul 29Laekna, Inc. to Report First Half, 2025 Results on Aug 13, 2025Laekna, Inc. announced that they will report first half, 2025 results on Aug 13, 2025
お知らせ • Jun 30Laekna, Inc. Submits Investigational New Drug Application to the U.S. Food and Drug AdministrationThe board of directors of Laekna, Inc. announced that the Group has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to metabolic patients who are in need of novel treatment options. The Group plans to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans.
お知らせ • Jun 24Laekna Presents Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123Laekna announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation and has taken place in Chicago, USA, from June 20 to 23 this year. Professor Xuening LI, Zhongshan Hospital affiliated to Fudan University,Principal Investigator of the Phase I Clinical Trial of LAE102 in China. At the ADA Scientific Sessions, Laekna showcased LAE102, LAE102, LAE 103, and LAE123 - an innovative portfolio targeting the ActRII pathway - highlighting team's extensive expertise and leadership in this field. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively.
お知らせ • Jun 23Laekna, Inc. Announces Results of Phase I Sad Study of Lae102Laekna, Inc. announced that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). Presentations details are as follows: Poster No.1. Abstract Number: 2205-LB, Title: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy volunteers, Time: Sunday, June 22, 2025, 12:30 p.m.-13:30 p.m. CST, Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous (IV) and subcutaneous (SC) cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events (TEAEs) leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123. This positions LAE102 as a promising drug candidate for achieving quality weight control.
お知らせ • May 13Laekna, Inc., Annual General Meeting, Jun 03, 2025Laekna, Inc., Annual General Meeting, Jun 03, 2025, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai China
お知らせ • Mar 26Laekna, Inc. Commences Study Recruitment in Phase I Multiple Ascending Dose Study of Lae102 for the Treatment of ObityThe board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I multiple ascending dose study of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.
お知らせ • Mar 10Laekna, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025Laekna, Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025
お知らせ • Jan 13Laekna, Inc. Announces Completion of A Successful Phase I Single Ascending Dose Study of Lae102 for the Treatment of ObesityThe board of directors of Laekna, Inc. announced that the Group has successfully completed the phase I single ascending dose study of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2+-2.2 kg/m2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study in China as well as the phase I clinical study in collaboration with Eli Lilly & Company in the U.S. The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible. The positive SAD Study results support continuing the investigation of LAE102 for thetreatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.